Renal outcomes in hypertensive Black patients at high cardiovascular risk

Kidney International

Volumn 81, Issue 6, 2012, Pages 568-576

  Weir, Matthew R ^a   Bakris, George L ^b   Weber, Michael A ^c   Dahlof, Bjorn ^d   Devereux, Richard B ^e   Kjeldsen, Sverre E ^f   Pitt, Bertram ^g   Wright, Jackson T ^h   Kelly, Roxzana Y ⁱ   Hua, Tsushung A ⁱ   Hester, R Allen ⁱ   Velazquez, Eric ^j   Jamerson, Kenneth A ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c Downstate Health Sciences University   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Blacks; cardiovascular disease; hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; ETHNIC GROUP; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 84857709990     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.417     Document Type: Article

References (22)

1. Dustan HP, Curtis JJ, Luke RG et al. Systemic hypertension and the kidney in black patients. Am J Cardiol 1987; 60: 73-77.
2. Easterling RE. Racial factors in the incidence and causation of end-stage renal disease (ESRD). Trans Am Soc Artif Intern Organs 1977; 23: 28-32. (Pubitemid 9078671)
3. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988; 12: 285-290.
4. Rostand SG, Kirk KA, Rutsky EA et al. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306: 1276-1279. (Pubitemid 12100210)
5. Weir MR, Hanes DS. Hypertension in African Americans: a paradigm of metabolic disarray. Semin Nephrol 1996; 16: 102-109. (Pubitemid 26084185)
6. Anderson NB, McNeilly M, Myers H. Autonomic reactivity and hypertension in blacks: a review and proposed model. Ethn Dis 1991; 1: 154-170.
7. Campese VM, Romoff MS, Levitan D et al. Abnormal relationship between sodium intake and sympathetic nervous system activity in salt-sensitive patients with essential hypertension. Kidney Int 1982; 21: 371-378. (Pubitemid 12136674)
8. Levy SB, Talner LB, Coel MN et al. Renal vasculature in essential hypertension: racial differences. Ann Intern Med 1978; 88: 12-16.
9. Luft FC, Grim CE, Fineberg N et al. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation 1979; 59: 643-650. (Pubitemid 9154955)
10. Luft FC, Rankin LI, Bloch R et al. Cardiovascular and humoral responses to extremes of sodium intake in normal black and white men. Circulation 1979; 60: 697-706. (Pubitemid 9254074)
11. Weir MR, Tuck ML. Essential hypertension in blacks: is it a metabolic disorder? Am J Kidney Dis 1993; 21: 58-67. (Pubitemid 23135499)
12. Weir MR. Salt intake and hypertensive renal injury in African-Americans. A therapeutic perspective. Am J Hypertens 1995; 8: 635-644.
13. Saunders E, Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713. (Pubitemid 20240985)
14. Weir MR, Gray JM, Paster R et al. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26: 124-130.
15. Weir MR, Weder A, for the MIST Study Group. Influence of race and dietary salt on blood pressure (BP) responses in salt sensitivity hypertensives (abstract). Hypertension 1997; 10: 19A.
16. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728. (Pubitemid 32525368)
17. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
18. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
19. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192.
20. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960; 21: 21-27.
21. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
22. Matsui Y, Eguchi K, O'Rourke MF et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54: 716-723.